‘VX-950, an investigational compound being developed by Vertex Pharmaceuticals, was well-tolerated and demonstrated potent antiviral activity in a 14-day phase Ib study in patients with hepatitis C.

According to the company, the rapid decline in plasma hepatitis C virus-RNA levels observed in patients taking VX-950, together with a viral kinetic analysis that projects the potential duration of treatment required to achieve sustained virologic response, support the evaluation of VX-950 in a novel, three-month combination treatment paradigm.’

Read more at Positive early trial for Vertex drug

Recent Entries

• Sigma Pharmaceuticals year profit rises 27 pct
• South African citizens cheap drug guinea pigs
• Two drugs test victims face a year in coma
• Can drug companies improve their reputation?
• Pfizer Sees 40 Percent Rise in 2006 Net on Cost Cuts
• Pfizer’s Forecast Disappoints
• Pharmaceutical RFID Adoption Stalls
• Inhalable Drug Might Bring Sigh Of Relief To Diabetes Patients
• GlaxoSmithKline unveils best results since merger
• Pfizer Sues Teva, Sandoz Over Zithromax

This entry was posted on Monday, November 14th, 2005 at 1:51 pm and is filed under General. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.